Mark Long was president of the Indiana University Research & Technology Corp., which was responsible for the university’s tech transfer, before launching a consulting firm, Long Performance Advisors, in 2008.
Indiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched a website that aims to keep that talent in the state.
Eli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly version of diabetes drug Byetta, a potential billion-dollar drug.
Amy Zucker is president of Indianapolis-based Synergy Marketing Group. Her firm was recently hired by Indianapolis-based ImmuneWorks Inc. to use a new website and search engine optimization to help recruit patients for a Phase 1 trial of ImmuneWorks experimental medicine idiopathic pulmonary fibrosis. The Web strategy is a new wrinkle on patient recruitment—in addition to the traditional partnerships with disease specialists at academic medical centers—that Zucker hopes leads to lower costs and faster clinical trials. Phase 1 clinical trials cost nearly $16,000 per patient.
The company, which develops mass spectrometry devices used in the life sciences and industrial chemistry, has a new CEO, among other changes.
Biomet’s quarterly results are considered an indicator on the state of the orthopedic device industry because it reports results before most of its competitors.
In combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread of breast cancer in some patients with a certain type of aggressive tumor.
California-based life sciences firm Beckman Coulter Inc. is planning its third local expansion since 2007, investing $18.2 million in its Indianapolis operation and adding as many as 95 jobs here in the next three years.
Community Health now has about 550 physicians, either on its payroll or committed through integration contracts, who have some of their pay hinge on measures of quality and communication. CEO Bryan Mills says the hospital system is looking to add even more.
Grand Valley Hybrids has been growing and conditioning hybrid seed corn in the West since 1946.
Eli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic version of the Evista osteoporosis treatment before March 2014.
The government's allegations read like a spy novel: Dr. Ke-xue "John" Huang lands a job at Indianapolis-based Dow AgroSciences and over five years works himself into a position of trust, with access to trade secrets and processes the company has invested $300 million to develop.
A federal indictment unsealed Tuesday in Indianapolis charged 45-year-old Ke-xue "John" Huang
with theft and attempted
theft of trade secrets to benefit a foreign government.
Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital,
Clarian Health Ventures and the Indiana Future Fund.
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
Orthopedics giant Biomet Inc. plans to invest $26 million to grow operations in its hometown of Warsaw, adding 278 jobs by
the end of 2012.
The Indiana Clinical and Translational Sciences Institute awarded $750,000 to 10 teams of researchers.
Indianapolis-based Dow AgroSciences improved sales and profit in its second quarter thanks to higher volumes and lower costs,
the company said Tuesday morning.
Venture dollars for Hoosier companies are still few, but the flow of deals is picking up.
Investors are focused on whether Eli Lilly and Co. can continue dividend payments when patent expirations hit in the new few
years and whether the company's drug development pipeline can replace lost revenue.
